
Approximately 2,500 patients are expected to be eligible to receive the one-time therapy

If approved, the treatment would be the first gene therapy in the US for this indication

Approximately 20,000 adults are affected by haemophilia A across more than 70 countries in Europe, the Middle East and Africa

The decision follows data suggesting BioMarin’s experimental gene therapies may have the potential to progress cancers

The study for BMN 307 in genetic disease phenylketonuria will be paused while malignancies in mice are explored

Vowed to break patent if company goes ahead with proposed price

Updated results presented at ASH 2019

Haemophilia candidate valrox will be a game-changer for company

Doubts remain on longer term efficacy

Palyniq is significant, but gene therapy pipeline most anticipated